What Is BPC-157

BPC-157 (Body Protection Compound 157) is a synthetic peptide composed of 15 amino acids, derived from a protective protein naturally present in human gastric juice. It has been studied primarily in animal models for its capacity to accelerate healing of tendons, ligaments, muscles, and gastrointestinal tissue. BPC-157 is not approved for human clinical use by any major regulatory body and remains classified as a research compound.

Tissue repair slows with age. Tendons, ligaments, and gut lining lose regenerative capacity as growth factor signaling diminishes and chronic low-grade inflammation accumulates. This deceleration contributes to musculoskeletal fragility, joint degeneration, and increased intestinal permeability, all of which compound over time and narrow the window of functional healthspan.

BPC-157 has attracted attention in the longevity and performance communities because it appears, at least in animal studies, to address several of these repair pathways simultaneously. Its gastric origin and relative acid stability make it unusual among peptides, and its reported effects span multiple tissue types. For anyone interested in maintaining structural integrity and gut function across decades, the mechanism of action is worth understanding, even as the human evidence base remains thin.

BPC-157 operates through several overlapping biological mechanisms. The most consistently observed is the upregulation of growth factors involved in tissue repair, particularly vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). By stimulating angiogenesis (the formation of new blood vessels), BPC-157 appears to improve blood supply to damaged tissue, creating the conditions necessary for fibroblasts and other repair cells to do their work. In animal models, this has translated to faster tendon reattachment, accelerated bone fracture healing, and improved muscle recovery after crush injuries.

At the gastrointestinal level, BPC-157 interacts with the nitric oxide (NO) system, which regulates blood flow, inflammation, and mucosal defense in the gut lining. Animal studies show it can protect against gastric ulcers induced by alcohol, NSAIDs, and stress, and it appears to promote the integrity of tight junctions between epithelial cells. This mechanism is relevant to intestinal permeability, a condition in which the gut barrier becomes excessively permeable, allowing bacterial endotoxins to enter circulation and drive systemic inflammation.

BPC-157 also modulates the dopamine and serotonin systems. In rat models, it has demonstrated protective effects against dopaminergic neurotoxicity and has influenced behavior in ways that suggest interaction with central neurotransmitter pathways. Additionally, it appears to counteract some effects of corticosteroid-induced tissue damage and to modulate the inflammatory cascade by influencing cytokine expression. The peptide's ability to affect multiple signaling systems simultaneously is part of what makes it difficult to characterize through a single mechanism, and part of what makes interpreting the evidence complex.

BPC-157 is available in two primary forms: injectable and oral. The injectable form, typically supplied as a lyophilized (freeze-dried) powder that is reconstituted with bacteriostatic water, is administered subcutaneously. Users often inject near the site of injury under the rationale that local delivery maximizes tissue concentration, though systemic distribution also occurs. Intramuscular injection is less common but used by some practitioners.

Oral forms include capsules and, less commonly, sublingual preparations. BPC-157 is notably stable in gastric acid, which is unusual for a peptide and consistent with its origin in gastric juice. This stability makes oral administration plausible for gastrointestinal targets, and some users report benefit from capsules for gut-related conditions. However, whether oral dosing achieves sufficient systemic levels to affect distant tissues like tendons or joints is unclear, since absorption and bioavailability data from human studies are not available.

Some compounding pharmacies have produced nasal spray formulations, though this delivery route has even less supporting data. The choice between injection and oral administration is typically guided by whether the target is local (musculoskeletal) or systemic/gastrointestinal, but this guidance is based on user reports and theoretical reasoning rather than comparative pharmacokinetic studies.

No clinically validated human dosage exists for BPC-157. The most commonly referenced doses in self-experimentation communities range from 250 to 500 micrograms per day, administered once or twice daily. Some users divide the dose between a morning and evening injection, while others use a single daily dose. Cycle lengths typically run four to six weeks, often followed by a period of discontinuation, though the rationale for cycling is based on general peptide use patterns rather than BPC-157-specific data.

Animal study doses are often cited in the range of 10 micrograms per kilogram of body weight, which scales to roughly 700 to 800 micrograms per day for an average adult human, though allometric scaling from rodents to humans is inherently imprecise. Higher doses have not been shown in animal literature to produce proportionally greater effects, and there is no established dose-response curve from human data. Users pursuing gut-specific benefits sometimes use higher oral doses on the assumption that much of the peptide acts locally before systemic absorption, but this remains speculative.

Peptide quality is a critical concern with BPC-157 because the market includes products from research chemical suppliers, compounding pharmacies, and direct-to-consumer vendors of widely varying reliability. A certificate of analysis (COA) from an independent third-party laboratory is the minimum standard to verify. Key items on a COA include peptide purity (typically reported via HPLC, with 98% or higher considered acceptable), mass spectrometry confirmation of molecular weight, and endotoxin testing results.

Compounding pharmacies operating under state pharmacy board oversight provide a more controlled supply chain than research chemical vendors. Following the FDA's 2023 actions, the availability of compounded BPC-157 has shifted, but some pharmacies continue to produce it under specific conditions. Products sold as "BPC-157" from international peptide vendors without COAs carry risks of contamination with heavy metals, bacterial endotoxins, or incorrect peptide sequences. Lyophilized powder that arrives as a white, fluffy cake and dissolves clearly in bacteriostatic water is a basic visual quality indicator; powder that appears discolored, clumped, or fails to dissolve should not be used.

The evidence base for BPC-157 is substantial in quantity but narrow in quality. Hundreds of published studies exist, nearly all conducted in rodent models by a relatively small group of research teams, many based in Croatia. These animal studies have demonstrated effects across an impressive range of tissues: tendons, muscles, bones, gut mucosa, blood vessels, and even neural tissue. The consistency of positive outcomes in these controlled animal settings is notable, but this body of work has not yet been replicated widely by independent laboratories, and the leap from rodent physiology to human application is significant.

Human clinical data is extremely limited. A small number of trials have been registered or conducted, but published results from well-designed, placebo-controlled human studies are sparse. Much of what is known about human response comes from anecdotal reports within the biohacking and sports medicine communities. In 2023, the FDA placed BPC-157 on a list of substances that compounding pharmacies cannot produce without an approved new drug application, reflecting the regulatory view that insufficient safety and efficacy data exist. The absence of pharmacokinetic studies in humans means that absorption rates, half-life, optimal dosing, and tissue distribution remain unknown in any rigorous sense.

The primary risk of BPC-157 use is the absence of established human safety data. Because the peptide promotes angiogenesis, there is a theoretical concern that it could support tumor vascularization in individuals with undetected or existing cancers. Product quality is another serious consideration: peptides sourced from unregulated manufacturers may contain contaminants, incorrect dosages, or degraded material. Injection-site reactions, nausea, dizziness, and lightheadedness have been reported anecdotally. Drug interactions are unstudied. Anyone with a history of cancer, active malignancy, or conditions involving abnormal blood vessel growth should weigh these unknowns carefully before use.